Characteristic | Node negative cohort (n=452) | SLN–ITC cohort (n=42) | P value† |
Year of surgery | <0.01 | ||
2012–14 | 44 (9.7) | 2 (4.8) | |
2015–17 | 308 (68.1) | 12 (28.6) | |
2018–19 | 100 (22.1) | 28 (66.7) | |
Age at surgery (years) (mean (SD)) | 62.5 (9.7) | 60.8 (10.6) | 0.29 |
Body mass index (kg/m2) (mean (SD)) | 35.3 (8.4) | 34.7 (9.7) | 0.69 |
Tumor diameter (mm) (median (IQR)) | 32 (21, 43) | 34 (25, 43) | 0.62 |
Grade | 0.26 | ||
1 | 347 (76.8) | 29 (69.0) | |
2 | 105 (23.2) | 13 (31.0) | |
LVSI | <0.01 | ||
No | 445 (98.5) | 35 (83.3) | |
Yes | 7 (1.5) | 7 (16.7) | |
Myometrial invasion | 0.86 | ||
None | 124 (27.4) | 11 (26.2) | |
<50% | 328 (72.6) | 31 (73.8) | |
Peritoneal cytology | 0.20 | ||
Negative | 353 (78.1) | 28 (66.7) | |
Positive | 29 (6.4) | 5 (11.9) | |
Not sampled | 70 (15.5) | 9 (21.4) |
Values are number (%) unless otherwise indicated.
*All patients considered FIGO stage IA.
†Comparisons between groups were evaluated using the two sample t test for age and body mass index, Wilcoxon two sample test for tumor diameter, and the χ2 or Fisher’s exact test for each of the categorical variables.
FIGO, International Federation of Gynecology and Obstetrics; ITC, isolated tumor cell; LVSI, lymphovascular space invasion.